These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38302139)

  • 1. Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
    Aebersold H; Foster-Witassek F; Aeschbacher S; Beer JH; Blozik E; Blum M; Bonati L; Conte G; Coslovsky M; De Perna ML; Di Valentino M; Felder S; Huber CA; Moschovitis G; Mueller A; Paladini RE; Reichlin T; Rodondi N; Stauber A; Sticherling C; Szucs TD; Conen D; Kuhne M; Osswald S; Schwenkglenks M; Serra-Burriel M;
    Open Heart; 2024 Jan; 11(1):. PubMed ID: 38302139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach.
    Serra-Burriel M; Aebersold H; Foster-Witassek F; Coslovsky M; Rodondi N; Blum MR; Sticherling C; Moschovitis G; Beer JH; Reichlin T; Krisai P; Aeschbacher S; Paladini RE; Kühne M; Osswald S; Conen D; Felder S; Schwenkglenks M;
    Value Health; 2023 Dec; 26(12):1721-1729. PubMed ID: 37741443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
    Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
    Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
    Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
    PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
    van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
    Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
    Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
    J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.
    Noviyani R; Youngkong S; Nathisuwan S; Bagepally BS; Chaikledkaew U; Chaiyakunapruk N; McKay G; Sritara P; Attia J; Thakkinstian A
    BMJ Evid Based Med; 2022 Aug; 27(4):215-223. PubMed ID: 34635480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in oral anticoagulant prescription in patients with nonvalvular atrial fibrillation in Flanders and the impact of switching patients from vitamin K antagonists to DOACS in terms of the burden caused by complications of the disease: a registry-based study.
    Nakhoul E; Vaes B; Mamouris P; Degryse JM
    Acta Clin Belg; 2023 Aug; 78(4):261-269. PubMed ID: 36172878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
    Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
    Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS
    BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
    Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.